Sign In
Buy PSTV
$4.08
+0.100 (+2.51%)
At Close: Jun 23, 2026
Plus Therapeutics to Provide Business Update Call on June 30, 2026
07:30am, Tuesday, 23'rd Jun 2026
Management to update on 2026 mid-year progress, milestones and provide details on its integrated CNS oncology strategy and artificial intelligence plans Management to update on 2026 mid-year progress,
Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform
12:22pm, Thursday, 04'th Jun 2026
Plus Therapeutics Inc (NASDAQ:PSTV) said its CNSide Diagnostics unit has received accreditation from the College of American Pathologists, a widely recognized standard in laboratory quality, sending
Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform
08:17am, Thursday, 04'th Jun 2026
Plus Therapeutics Inc (NASDAQ:PSTV) said its CNSide Diagnostics unit has received accreditation from the College of American Pathologists, a widely...
Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory
07:30am, Thursday, 04'th Jun 2026
HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company advancin
Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases
07:30am, Tuesday, 26'th May 2026
Plus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-making reducing healthcare costs by 40%
Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology
07:30am, Tuesday, 19'th May 2026
Partnership to deliver a novel AI-native integrated CNS oncology platform Platform will unify and analyze Plus' proprietary therapeutic, diagnostic, and bioinformatics datasets to accelerate precision
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
06:20pm, Friday, 15'th May 2026
Plus Therapeutics (PSTV) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to a loss of $14 per share a year ago.
HOUSTON, May 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceu
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
11:39am, Thursday, 14'th May 2026
CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin glioblastoma story.
Plenary session at AANS underscores REYOBIQ's potential as a differentiated targeted radiotherapeutic platform for CNS cancers Plenary session at AANS underscores REYOBIQ's potential as a differentiat
Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic
07:30am, Thursday, 07'th May 2026
HOUSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiop
Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
07:30am, Tuesday, 28'th Apr 2026
Expands access by 6 million covered lives, advancing commercial momentum for CNSide® in metastatic CNS cancers Expands access by 6 million covered lives, advancing commercial momentum for CNSide® in
HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radi
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 22'nd Apr 2026
HOUSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceutica
Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
07:30am, Tuesday, 21'st Apr 2026
HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceutica
